¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"contrast enhancement ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • contrast bath
    ¿Â³Ã±³´ë¸ñ¿å
  • contrast echocardiography
    Á¶¿µ½É(Àå)ÃÊÀ½ÆÄ°Ë»ç, Á¶¿µ½É(Àå)ÃÊÀ½ÆÄ(¼ú)
  • contrast enema
    1. Á¶¿µ°üÀå 2. Á¶¿µ°üÀå¾×
  • contrast material
    Á¶¿µÀç
  • contrast media
    Á¶¿µÁ¦
  • contrast medium
    Á¶¿µÁ¦
  • contrast stain
    ´ëÁ¶¿°»ö
  • contrast staining
    ´ëÁ¶¿°»ö(¹ý)
  • dynamic susceptibility contrast technique
    ¿ªµ¿ÀÚÈ­À²´ëÁ¶±â¹ý
  • double contrast radiography
    ÀÌÁßÁ¶¿µ¹æ»ç¼±ÃÔ¿µ(¼ú)
  • double-contrast barium enema
    ÀÌÁßÁ¶¿µ¹Ù·ý°üÀå
  • hepatorenal echo contrast
    °£ÄáÆÏ¸Þ¾Æ¸®´ëÁ¶, °£½ÅÀå¿¡ÄÚ´ëÁ¶
  • magnetic transfer contrast
    ÀÚ±âÈ­Àü´Þ´ëÁ¶µµ
  • phase-contrast microscope
    À§»óÂ÷Çö¹Ì°æ
  • proton density contrast
    ¾ç¼ºÀڹеµ´ëÁ¶
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • periventricular enhancement
    ³ú½ÇÁÖÀ§Á¶¿µÁõ°­
  • rim enhancement
    Å×Áõ°­
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
  • 3D phase contrast angiography
    »ïÂ÷¿øÀ§»ó´ëÁ¶Ç÷°üÁ¶¿µ¼ú
  • contrast agent
    Á¶¿µÁ¦
  • barium contrast medium
    ¹Ù·ýÁ¶¿µÁ¦
  • binocular contrast
    ¾ç¾È´ëºñ, µÎ´«´ëºñ
  • blood oxygenation level dependant contrast
    Ç÷Áß»ê¼ÒÄ¡ÀÇÁ¸´ëÁ¶µµ
  • contrast bath
    ¿Â³Ã±³´ë¸ñ¿å
  • contrast
    ´ëÁ¶
  • color contrast
    »ö´ëºñ, »ö´ëÁ¶
  • contrast echocardiography
    Á¶¿µ½ÉÀåÃÊÀ½ÆÄ°Ë»ç, Á¶¿µ½ÉÃÊÀ½ÆÄ°Ë»ç
  • contrast enema
    Á¶¿µ°üÀå
  • contrast material
    Á¶¿µÀç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • T1 contrast
    T1 ´ëÁ¶µµ
  • T2 contrast
    T2 ´ëÁ¶µµ
  • gadolinium (Gd) based contrast agent
    °¡µ¹¸®´½ Á¶¿µÁ¦
  • good contrast
    ¶Ñ·ÇÇÑ ´ëÁ¶µµ
  • hepato renal echo contrast
    °£ ½ÅÀå ¿¡ÄÚ ´ëÁ¶
  • hepato-renal echo contrast
    °£-½ÅÀå (ÊÜ-ãìíô) ¿¡ÄÚ ´ëÁ¶ (ÓßðÎ), °£-½ÅÀå (ÊÜ-ãì
  • phase contrast
    À§»ó ´ëÁ¶
  • phase contrast (PC) MR angiography
    À§»ó ´ëÁ¶ ÀÚ±â°ø¸í Ç÷°üÁ¶¿µ¼ú
  • phase contrast microscopy
    À§»óÂ÷(êÈßÓó¬)Çö¹Ì°æ°Ë»ç
  • phase-contrast microscopy
    À§»óÂ÷Çö¹Ì°æ
  • positive contrast medium
    ¾ç¼º Á¶¿µÁ¦
  • pre contrast enhanced image
    Á¶¿µ Áõ°¡Àü ¿µ»ó
  • proton density contrast
    ¾çÀÚ ¹Ðµµ ´ëÁ¶
  • DeRitis ratio
    µå¸®Æ¼½ººñÀ²
  • Donnan ratio
    µ·³­À²
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immune enhancement
    ¸é¿ªÇÐÀûÃËÁø (Á¾¾çÁõ½ÄÀÇ)
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • inflow enhancement
    À¯ÀÔ Áõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µÁõ°­, °æµµÀÇ Á¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³Àû Á¶¿µÁõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ® Á¶¿µÁõ°­
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­.
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­(åÕпý­ñòË­)
  • posterior echo enhancement
    ÈÄ¹æ ¿¡ÄÚ Áõ°­, ÈÄ¹æ ¸Þ¾Æ¸®Áõ°­
  • posterior echo enhancement
    ÈĹæ (ý­Û°) ¿¡ÄÚ Áõ°­ (ñòË­), ÈĹæ (ý­Û°) ¸Þ¾Æ¸® ?
  • proton relaxation enhancement
    ¾çÀÚ ÀÌ¿Ï Áõ°­
  • rapid acquisition with relaxation enhancement (RARE)
    ±Þ¼Ó ȹµæ ÀÌ¿Ï Áõ°­
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • base ratio
    ¿°±âºñ(ç¤ÐñÝï)
  • channels ratio method
    ä³Î ºñÀ²¹ý(Ýï×ËÛö)
  • coding ratio
    ºÎÈ£ºñ(ݬûÜÝï)
  • dichroic ratio
    ÀÌ»öºñ(ì£ßäÝï)
  • disequilibrium ratio
    ºÒÆòÇü ºñÀ²(ÝÕøÁû¬Ýï×Ë)
  • dissymmetry ratio
    ºÒ¿ÏÀü´ëĪ ºñÀ²(ÝÕèÇîïÓßöàÝï×Ë)
  • distribution ratio
    "ºÐÆ÷À²(ÝÂøÖëÒ), (ÔÒ) partition coefficient"
  • Donnan ratio
    µ·³­ À²(ëÒ)
  • extraction ratio
    ÃßÃâºñ(õÎõóÝï)
  • flux ratio method
    Çöô½º ºñÀ²¹ý(Ýï×ËÛö)
  • frictional ratio
    ¸¶Âûºñ(ؤóÍÝï)
  • G + C/A + T ratio
    G + C/A + T ºñ(Ýï)
  • gyromagnetic ratio
    ÀÚ±âȸÀü ºñ(í¸Ñ¨üÞï®Ýï)
  • ratio
    ºñÀ²(Ýï×Ë)
  • induction ratio
    À¯µµºñ(ë¯ÓôÝï)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dense enhancement
    °­ÇÑ Á¶¿µÁõ°­
  • edge enhancement
    º¯¿¬Áõ°­
  • enhancement
    Áõ°­
  • flow related enhancement
    À¯µ¿°ü·ÃÁõ°­
  • gradient echo technique magnetic susceptibility proton relaxation enhancement
    °æ»ç¿¡ÄÚ¹ý±âÈ­À²¼ºÀÚÀÌ¿ÏÁõ°­
  • inflow enhancement
    À¯ÀÔÁõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÀÇÁ¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³ÀûÁ¶¿µÁõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º¾çÀÚÀÌ¿ÏÁõ°­
  • peripheral linear enhancement
    ¸»Ãʼ±ÇüÁ¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • posterior echo enhancement
    ÈĹ濡ÄÚÁõ°­, ÈĹæ¸Þ¾Æ¸®Áõ°­
  • proton relaxation enhancement
    ¾çÀÚÀÌ¿ÏÁõ°­
  • rapid acquisition with relaxation enhancement [=RARE]
    ÀÌ¿ÏÁõ°­±Þ¼Óȹµæ
  • rim enhancement
    Å׵θ®Á¶¿µÁõ°­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
L/S lactase/sucrase [ratio]; lecithin/ sphingomyelin [ratio]; lipid/saccharide [ratio]; longitudinal sec...
CNR cannabinoid receptor; Center for Nursing Research; contrast-to-noise ratio; Council of Nurse Researc...
ADE acute disseminated encephalitis; adverse drug event; antibody-dependent enhancement; apparent digest...
DEPT distortionless enhancement by polarization transfer
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CNR Contrast-to-Noise Ratio
C/N Contrast-to-noise ratio
L/S ratio Lecithin/sphingomyelin ratio
ADE Antibody-dependent enhancement
EF Enhancement factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • contrast
    ´ëÁ¶µµ, ´ëÁ¶¹ý, ´ëºñ
    ÁÖÀ§ ¶Ç´Â ¾ÈÂÊ¿¡ µé¾îÀÖ´Â ¸Å°³ ¹°Áú, ±×¸®°í ´ëÁ¶ ¸ÅÁú°ú ÁÖÀ§ Á¶Á÷¿¡ ÀÇÇÑ x¼±ÀÇ Èí¼ö¿¡¼­ÀÇ Â÷ÀÌ ¶§¹®¿¡ »ý±ä´Ù. ±¸Á¶ÀÇ ¹æ»ç¼±Àû ½Ã°¢È­ÀÌ´Ù.
  • contrast color
    ´ëºñ»ö
  • contrast material
    Á¶¿µ ¹°Áú, Á¶¿µÁ¦
  • contrast medium
    Á¶¿µÁ¦
    ¾î¶² Á¶Á÷À̳ª °ø°£À» ¹æ»ç¼± ºÒÅõ°ú¼ºÀ¸·Î ¸¸µå´Â ¿µ»ó °Ë»ç¿¡ ¾Õ¼­ ÁÖ»çÇÏ´Â ¹æ»ç¼± ºÒÅõ°ú¼º ¹°Áú.
  • double contrast
    ÀÌÁß Á¶¿µ¼ú
  • double contrast arthrography
    ÀÌÁß °üÀý Á¶¿µ¼ú, ÀÌÁß Á¶¿µ °üÀý Á¶¿µ¼ú
  • hepato renal echo contrast
    °£ ½ÅÀå ¿¡ÄÚ ´ëÁ¶
  • magnetic transfer contrast
    ÀÚÈ­ Àü´Þ ´ëÁ¶µµ
  • phase contrast
    À§»ó ´ëÁ¶
  • pre-contrast enhanced image
    Á¶¿µ Áõ°­Àü ¿µ»ó
  • proton density contrast
    ¾çÀÚ ¹Ðµµ ´ëÁ¶
  • radiographic contrast
    ¹æ»ç¼± »çÁø ´ëÁ¶
  • radiopaque contrast medium
    ¹æ»ç¼± ºÒÅõ°ú¼º Á¶¿µÁ¦
  • single contrast arthrogram
    ´ÜÀÏ ´ëºñ °üÀý Á¶¿µ »çÁø
  • single-contrast arthrography
    ´ÜÀÏ °üÀý Á¶¿µ¼ú
    °üÀý ¿øÆÇÀÇ À§Ä¡, ¿¬Á¶Á÷ ¿ÜÇü, õ°øÀÇ À¯¹«, °üÀý ¿îµ¿, °üÀý³» À̹°Áú, À¯Âø¼º °üÀý³¶¿°À» Æ÷ÇÔÇÏ´Â °üÀý³» ¿¬Á¶Á÷ÀÇ À§Ä¡¿Í ¿ÏÀü¼ºÀ» È®ÀÎÇϱâ À§ÇØ °üÀý°­ ³»¿¡ ¹æ»ç¼± ºÒÅõ°ú¼º Á¶¿µÁ¦¸¦ ÁÖ»çÇÑ ÈÄ ÃÔ¿µÇÑ °üÀý »çÁø.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
radiopaque contrast A radiopaque substance (for example metal) will be highlighted (appear white) on a plain X-ray. The use of iodine containing radiopaque contrast dyes allow enhancement of the anatomy demonstrable with conventional X-ray.
(27 Sep 1997)
radiopaque contrast dye A radiopaque substance (for example metal) will be highlighted (appear white) on a plain X-ray. The use of iodine containing radiopaque contrast dyes allow enhancement of the anatomy demonstrable with conventional X-ray.
(27 Sep 1997)
radiopaque contrast material A radiopaque substance (for example metal) will be highlighted (appear white) on a plain X-ray. The use of iodine containing radiopaque contrast dyes allow enhancement of the anatomy demonstrable with conventional X-ray.
(27 Sep 1997)
phase-amplitude contrast <microscopy> The separation and recombination of direct vs. Diffracted rays in a light microscope adjusted to Kohler illumination. at the lower focal plane of the condenser there is an annular diaphragm with an opaque central stop. Through this diaphragm rays are focused as a hollow cone onto the specimen. In the back focal plane of the objective there is a conjugate annular diaphragm (phase plate). If here the undiffracted rays are retarded (by a transparent film of proper thickness on the annulus of the phase plate), bright contrast results. If, instead, the phase-delay film is on the central spot, dark contrast results. With either a bright or a dark-contrast phase plate, the annulus is usually coated with a partially absorbing (very thin) film of silver (Zernike method) or carbon soot (Wilska method) to reduce the higher amplitude (intensity) of the undiffracted rays.
(05 Aug 1998)
phase contrast <microscopy> An optical method devised by F. Zernike for converting the focused image of a phase object (one with differences in refractive index or optical path but not in absorbance), which ordinarily is not visible in focus, into an image with good contrast.
(05 Aug 1998)
phase-contrast microscope <instrument> A specially constructed microscope that has a special condenser and objective containing a phase-shifting ring whereby small differences in index of refraction are made visible as intensity or contrast differences in the image; particularly useful for examining structural details in transparent specimens such as living or unstained cells and tissues.
(05 Mar 2000)
phase contrast microscopy <investigation> A simple nonquantitative form of interference micoscopy of great utility in visualising live cells. Small differences in optical path length due to differences in refractive index and thickness of structures are visualised as differences in light intensity.
(18 Nov 1997)
microscopy, phase-contrast A form of interference microscopy in which variations of the refracting index in the object are converted into variations of intensity in the image. This is achieved by the action of a phase plate.
(12 Dec 1998)
colour-contrast microscope <instrument> A type of microscope in which the condenser stop is of one colour and the annulus is a complement of it so that unstained objects are observed in one colour on a field of the other.
(05 Mar 2000)
contrast A dye injected intravenously during X-ray studies, for example CT, to enhance the image of a tumour. In MR studies, the contrast is called gadolinium. The use of contrast may rarely result in some adverse effects: it also increases the cost (but also accuracy in many cases) of the scan.
(16 Dec 1997)
contrast agent A substance that is introduced into or around a structure and, because of the difference in absorption of X-rays by the contrast medium and the surrounding tissues, allows radiographic visualisation of the structure.
(18 Nov 1997)
contrast bath A bath in which a part is immersed in hot water for a period of a few minutes and then in cold, the hot and cold periods alternated regularly at intervals, usually half-hours; used to increase the blood flow to the part.
(05 Mar 2000)
contrast echocardiography The injection of contrast media of high echo reflectants (e.g., bubbles) to outline a chamber or delineate a shunt within the heart.
(05 Mar 2000)
contrast enema Enema using barium or another contrast medium.
(05 Mar 2000)
contrast material A substance that is introduced into or around a structure and, because of the difference in absorption of X-rays by the contrast medium and the surrounding tissues, allows radiographic visualisation of the structure.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • payout ratio
    ¹è´ç ¼ºÇâ
  • priceearnings ratio
    ÁÖ°¡ ¼öÀÍ·ü 9
  • ratio
    ºñ;ºñÀ²
  • respiratory quotient (ratio)
    È£Èí·ü;È£Èíºñ(³»¹ñ´Â ź»ê°¡½ºÀÇ ¾ç°ú ¿ÜºÎ·ÎºÎÅÍ Èí¼öÇÏ´Â »ê¼Ò·®°úÀÇ ºñ)
  • risk-benefit ratio
    À§Ç輺°ú ¼öÀͼº°úÀÇ ºñÀ²
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á